Skip to main content
. Author manuscript; available in PMC: 2022 Jun 22.
Published in final edited form as: Structure. 2022 Jun 17;30(9):1224–1232.e5. doi: 10.1016/j.str.2022.05.020

Figure 3. The ET domain of BRD4 is an additional target of SARS-CoV-2 E.

Figure 3.

(a) The SARS-CoV-2 E peptides tested. (b) Overlayed 1H,15N HSQC spectra of the 15N-labeled BRD4 ET domain recorded before and after gradual addition of the indicated SARS-CoV-2 E peptides. The spectra are color-coded according to the protein:peptide molar ratio. (c) Representative MST binding curves for the interaction of the BRD4 ET domain with the FAM-SARS-CoV-2 E55–66 peptide. Data are representative of two experiments, and error represents SEM. (d, e) Analysis of CSPs in the BRD4 ET domain induced by SARS-CoV-2 E55–66. Residues of the BRD4 ET domain that exhibited large chemical shift perturbations (greater than the average plus one standard deviation) upon addition of SARS-CoV-2 E55−66 are mapped onto the BRD4 ET structure (2JNS), labeled and colored orange in (d). Histogram of normalized CSPs in 1H,15N HSQC spectra of BRD4 ET induced by 10-fold molar excess of SARS-CoV-2 E55–66 as a function of residue is shown in (e). The dotted line indicates average chemical shift change plus one standard deviation. Side chain amide resonances are indicated by asterisk.